Healthcare

Outset Medical to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN JOSE, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering…

1 year ago

CirrusMD and Tendo Partner to Expand Choice and Savings for Employees and Their Dependents 

CirrusMD adds Tendo CareConnect Marketplace to provide more affordable, high-quality care options for patients needing in-person careDENVER and PHILADELPHIA, Jan.…

1 year ago

Transcarent To Acquire Accolade

Combined company creates industry leading platform with more than 1,400 employer and payer clients, with shared focus on consumer empowerment…

1 year ago

Foresight Diagnostics Provides 2025 Outlook and 2024 Year in Review

- Achieved 100% revenue growth versus prior year – - Received Investigational Device Exemption approval from the FDA for the…

1 year ago

SeaStar Medical Begins Shipping QUELIMMUNE to a Fourth Hospital Customer

DENVER, Jan. 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary…

1 year ago

CRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating…

1 year ago

Vericel to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025

CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine…

1 year ago

Now Open: VITAS® Healthcare Inpatient Hospice Unit in Fort Worth

Freestanding homelike facility for specialized end-of-life care will serve 500+ patients annuallyFORT WORTH, Texas, Jan. 08, 2025 (GLOBE NEWSWIRE) --…

1 year ago

Araris Biotech AG Announces Research Collaboration and Option to License Agreement with Chugai Pharmaceutical Co. to Develop Next-Generation ADCs Using Araris’ AraLinQ™ technology

Araris will use proprietary AraLinQ™ linker-conjugation platform to generate novel ADCs using antibodies against targets provided by ChugaiAraris to receive…

1 year ago

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

Continued Strong Clinical Progress and Planned New Combination Trial Provide Significant Momentum for 2025NEW YORK, Jan. 08, 2025 (GLOBE NEWSWIRE)…

1 year ago